drugset
drugset / Trial / NCT05909332

Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)

NCT05909332 ↗

Phase 3 Recruiting 764 enrolled Fudan University
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, open-label phase III clinical trial comparing antivascular therapy combined with standard chemotherapy and standard chemotherapy in adjuvant therapy for patients with triple-negative breast cancer, basal-like/Immune suppressed subtype.

Timeline

Start
2023-06-20
Primary completion
2029-05-30
Completion
2031-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject BP102 Monoclonal antibody 10 mg/kg Intravenous
Background Cyclophosphamide Other / unclassified 600 mg/m2 Intravenous
Background Epirubicin Small molecule 75 mg/m2 Intravenous
Background Epirubicin Small molecule 100 mg/m2 Intravenous
Background Paclitaxel Small molecule 125 mg/m2 —

Indications

triple-negative breast carcinoma